XW10508 is an orally active prodrug of esketamine, an NMDA receptor antagonist, which is under development for the treatment of major depressive disorder and chronic pain.
[1][5] XW10508 is being developed as once-daily orally administered extended-release and immediate-release formulations with misuse resistance.
[1][3] As of August 2024, XW10508 is in phase 2 clinical trials for major depressive disorder and is in phase 1 clinical trials for chronic pain.
[1][4][2] However, no recent development has been reported for these indications.
[1] The drug is being developed by XWPharma, which was previously known as XW Laboratories.